S

SNDX

SNDX

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
20%Bearish
Buy/Sell Ratio3% buys
BearishBullish
SNDX Live QuoteReal-time
$8.56
$4.69(-35.40%)1M
Day Range$8.47 – $9.41
Open$9.17
Previous Close$9.20
Volume3.47M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$786.85M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-2.37
Price to Book84.8
Dividend Yield0.65%
Beta (Volatility)0.45
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $8.56 (1%)
Low: $8.47High: $25.59
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$35.45-76.4% upside

Insider Buys

4

$242K

Insider Sales

17

$6.86M

Total Volume

$7.10M

21 transactions

Net Activity

$6.61M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
55CONFIDENCE

Sentiment Rating

Neutral / Balanced

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 97% of total transaction value.
  • •Cluster buying: 4 unique insiders purchased shares, showing strong alignment.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
  • •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
M
1

Metzger Michael A

CEO

0 buys8 sells

$4.40M total

B
2

Botwood Nicholas A.J.

Head of R, D, CMO

1 buys1 sells

$1.29M total

P
3

Podlesak Dennis

Dir

0 buys2 sells

$989K total

G
4

Goldan Keith A.

CFO

1 buys5 sells

$208K total

K
5

Katkin Keith

Dir

1 buys0 sells

$91K total

Trading History
SNDX insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 29, 2026

3 weeks ago

Podlesak Dennis

Dir

Director
Sell8.0K$14.21$114K

Jul 8, 2026

4 months ago

Metzger Michael A

CEO

CEO
Sell32.4K$24.24$785K

Jun 11, 2026

5 months ago

Botwood Nicholas A.J.

Head of R, D, CMO

C-Level
Sell65.5K$18.07$1.18M

Jun 1, 2026

5 months ago

Goldan Keith A.

CFO

CFO
Sell1.2K$18.99$22K

Jun 1, 2026

5 months ago

Metzger Michael A

CEO

CEO
Sell6.8K$18.99$130K

Feb 9, 2026

9 months ago

Metzger Michael A

CEO

CEO
Sell17.2K$21.03$361K

Feb 9, 2026

9 months ago

Goldan Keith A.

CFO

CFO
Sell3.4K$21.03$72K

Feb 6, 2026

9 months ago

Metzger Michael A

CEO

CEO
Sell7.4K$20.62$153K

Feb 6, 2026

9 months ago

Goldan Keith A.

CFO

CFO
Sell2.1K$20.62$43K

Sep 8, 2025

14 months ago

Metzger Michael A

CEO

CEO
Sell157.3K$16.41$2.58M

Aug 14, 2025

15 months ago

Podlesak Dennis

Dir

Director
Sell57.6K$15.19$875K

Jul 16, 2025

16 months ago

Goldan Keith A.

CFO

CFO
Sell1.3K$9.29$12K

Jul 16, 2025

16 months ago

Metzger Michael A

CEO

CEO
Sell7.5K$9.29$70K

May 19, 2025

18 months ago

Goldan Keith A.

CFO

CFO
Buy3.0K$0.00$0

May 16, 2025

18 months ago

Botwood Nicholas A.J.

Head of R, D, CMO

C-Level
Buy11.8K$9.00$106K

May 19, 2025

18 months ago

Huber Martin H. Jr.

Dir

Director
Buy5.0K$8.99$45K

May 19, 2025

18 months ago

Katkin Keith

Dir

Director
Buy10.0K$9.11$91K

Mar 4, 2025

20 months ago

Metzger Michael A

CEO

CEO
Sell7.8K$15.05$118K

Feb 10, 2025

21 months ago

Goldan Keith A.

CFO

CFO
Sell3.8K$15.50$59K

Feb 10, 2025

21 months ago

Metzger Michael A

CEO

CEO
Sell13.3K$15.50$206K

Feb 10, 2025

21 months ago

Gallagher Neil

Pres, Head of R, D

President
Sell4.6K$15.50$72K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
SNDX Buy Conviction3%
Industry Rank#475 of 563
Volume Contribution0.0%
Total Industry Activity$16.73B

SNDX has an insider buy conviction of 3%, compared to the Unknown sector buy average of 6%. SNDX ranks #475 in insider activity out of 563 tracked companies in its industry.

Insider Trading Summary & Commentary
Automated executive transaction analysis for SNDX

Over the last 90 days, corporate insiders at SNDX (SNDX) engaged in a total of 21 transactions reported via SEC Form 4 filings. Among these, 4 were open-market purchases and 17 were sales. The total volume of insider trading reached $7.10M.

The net insider activity for SNDX shows a net selling bias of $6.61M. This activity represents a 3% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Metzger Michael A (CEO), who traded 157.3K shares valued at $2.58M on Sep 8, 2025.

Live Market News & Developments
Aggregated real-time headlines for SNDX (SNDX)
6 updates

Syndax Pharmaceuticals (SNDX) Stock May Be Rich After Revuforj Award Win

Yahoo Finance16d ago

Syndax (SNDX) Sales Nearly Doubled, So Why Did The Stock Fall?

Yahoo Finance99d ago

Syndax Pharmaceuticals (SNDX) Stock Price, Chart & Analysis

www.debelegger.nl11d ago

SNDX - Syndax Pharmaceuticals Inc Stock Price and Quote

Finviz176d ago

Syndax Pharmaceuticals (SNDX) Missed On Q3 Results, Is The 65% Undervaluation Case Still Intact?

Yahoo Finance16d ago

Syndax Pharmaceuticals (SNDX) Stock May Trade At A Premium After A 38% Fall

Simply Wall St16d ago

FAQs About SNDX Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for SNDX.

Based on SEC Form 4 disclosures, the Insider Confidence Score for SNDX is currently 55/100, which reflects a neutral / balanced bias. This calculation accounts for a total of 4 purchases and 17 sales by company executives over the last 90 days.

The CEO Conviction Index for SNDX is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.